Adleap Tablet 7's

Adleap Tablet 7's belongs to a group of medicines known as androgen receptor inhibitors. It is used to treat prostate cancer. Cancer is a condition where cells in a specific body part grow and reproduce uncontrollably. The cancerous cells can attack and destroy surrounding healthy tissue, including organs. Prostate cancer is a type of cancer that only occurs in men and affects the prostate gland, a tiny gland under the bladder that produces semen.

Adleap Tablet 7's contains Enzalutamide, an androgen receptor blocker (inhibitor). Enzalutamide blocks testosterone from reaching prostate cancer cells. Most prostate cancers require testosterone to grow. This can slow the growth of the cancer and may shrink it.

Use this medicine as directed by your doctor. You may sometimes experience trouble breathing (pneumonia), weakness or feeling more tired than usual, back pain, diarrhoea, pain in your joints, swelling (in your hands, arms, legs or feet), muscle or bone pain, muscle weakness, headache, cold-like symptoms, dizziness, high blood pressure and trouble falling or staying asleep (insomnia). Most of these side effects may gradually resolve over time. However, if the side effects persist or worsen, consult your doctor.

Enzalutamide is only for use in men. Men using this Adleap Tablet 7's must use effective birth control whenever they have sex during your treatment and for three months after their final dose. In rare cases, Adleap Tablet 7's may cause seizures, so tell your doctor if you have or have ever had seizures. Because of the risk of seizure associated with Adleap Tablet 7's use, patients should be advised of the risk of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others. Consumption of alcohol is strictly avoided.

Adleap Tablet 7's is used in the treatment of Prostate Cancer. The detailed uses of Adleap Tablet 7's are as follows:

• Metastatic castration-resistant prostate cancer (mCRPC): Adleap Tablet 7's is used to treat prostate cancer that continues to progress despite low testosterone levels. It is typically prescribed when the cancer has spread to other parts of the body and no longer responds to hormone therapy.
• Non-metastatic castration-resistant prostate cancer (nmCRPC):Adleap Tablet 7's is used in patients whose prostate cancer has not yet spread but is no longer responding to medical or surgical treatments that lower testosterone.
• Hormone-sensitive metastatic prostate cancer: Adleap Tablet 7's is used in combination with androgen deprivation therapy (ADT) to treat prostate cancer that has spread but still responds to hormone-lowering treatments.

• Adleap Tablet 7's can be taken with or without food or as advised by your doctor.
• Follow your doctor's instructions on the dosage and timing of this medication.
• Swallow Adleap Tablet 7's as a whole with a glass of water.
• Do not crush, break, or chew it.

Adleap Tablet 7's contains Enzalutamide, which belongs to a group of medicines known as androgen receptor inhibitors. Most prostate cancers require testosterone to grow. In men, the testicles produce the majority of testosterone. Adrenal glands (Just above each kidney) produce a small quantity of testosterone. Enzalutamide is preventing testosterone from reaching cancer cells in the prostate. This can inhibit the growth of the cancer and even cause it to shrink.

Do not take Adleap Tablet 7's if you are allergic or hypersensitive to any component present in it. You must take Enzalutamide according to the instructions your doctor or pharmacist gives you. You must take Enzalutamide exactly as prescribed by your doctor or pharmacist. You must take the correct dose, not more or less. Consult your healthcare team before discontinuing Adleap Tablet 7's or missing a dose. Talk to your doctor before taking Adleap Tablet 7's if you have severe allergic reactions to medicines or foods or suffer from any medical illness. Use a condom or effective birth control method if you are having sex with pregnant women or women who can become pregnant.